Analyst Price Targets — ABT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 2, 2026 10:31 am | — | Barclays | $142.00 | $109.30 | TheFly | Abbott price target lowered to $142 from $169 at Barclays |
| January 29, 2026 5:17 pm | Ilya Zubkov | Loop Capital Markets | $120.00 | $106.09 | StreetInsider | Freedom Capital Markets Upgrades Abbott Labs (ABT) to Buy |
| January 23, 2026 1:26 pm | — | Evercore ISI | $138.00 | $108.61 | TheFly | Abbott price target lowered to $138 from $144 at Evercore ISI |
| January 23, 2026 12:42 pm | — | UBS | $132.00 | $108.60 | TheFly | Abbott price target lowered to $132 from $140 at Oppenheimer |
| January 23, 2026 12:13 pm | Anthony Petrone | Mizuho Securities | $125.00 | $108.60 | TheFly | Abbott price target lowered to $125 from $140 at Mizuho |
| January 23, 2026 12:05 pm | — | Piper Sandler | $135.00 | $108.60 | TheFly | Abbott price target lowered to $135 from $150 at Piper Sandler |
| January 23, 2026 11:56 am | — | Bernstein | $125.00 | $108.60 | TheFly | Abbott price target lowered to $125 from $154 at Bernstein |
| January 23, 2026 11:37 am | Larry Biegelsen | Wells Fargo | $122.00 | $108.60 | TheFly | Abbott price target lowered to $122 from $146 at Wells Fargo |
| January 9, 2026 11:47 am | Lee Hambright | Bernstein | $154.00 | $126.18 | TheFly | Abbott price target raised to $154 from $150 at Bernstein |
| January 9, 2026 10:46 am | — | Goldman Sachs | $152.00 | $126.18 | TheFly | Abbott price target lowered to $152 from $157 at Goldman Sachs |
Latest News for ABT
Abbott (ABT) closed at $114.12 in the latest trading session, marking a -1.92% move from the prior day.
Banco Santander S.A. reduced its holdings in Abbott Laboratories (NYSE: ABT) by 12.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,567 shares of the healthcare product maker's stock after selling 5,008 shares during the period. Banco
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) is up 9.39% YTD in 2026, decisively outperforming SPY's 1.08%. Dividend Aristocrats are regaining momentum after a weak 2025, with 55 outpacing SPY and 39 posting double-digit gains this year already. Dividend growth is lagging, with 2026's average increase currently at 3.22%, below last year's trend and potentially signaling headwinds.
Aster Capital Management DIFC Ltd acquired a new position in shares of Abbott Laboratories (NYSE: ABT) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 21,796 shares of the healthcare product maker's stock, valued at approximately $2,919,000. Abbott Laboratories comprises about 1.5% of
DNB Asset Management AS reduced its position in Abbott Laboratories (NYSE: ABT) by 6.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 464,128 shares of the healthcare product maker's stock after selling 34,333 shares during the period. DNB
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.